Cyclerion Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $6.9M
- Website
- http://www.cyclerion.com
- Introduction
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03892499
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-praliciguat
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03818295
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-olinciguat
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03795519
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03499106
- Locations
- 🇺🇸
IQVIA, Overland Park, Kansas, United States
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT03285178
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸MedStar Health Research Institute, MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Howard University Center for Sickle Cell Disease, Washington, District of Columbia, United States
- Prev
- 1
- 2
- 3
- Next